“How to Avoid and Respond to Public FDA Criticisms—Form 483 Letters—for Temperature, Humidity and other Controlled Environments”
(Vocus) April 29, 2010 -- “How to Avoid and Respond to Public FDA Criticisms—Form 483 Letters—for Temperature, Humidity and other Controlled Environments” is now available from Veriteq (www.veriteq.com), a Vaisala company, a leader in FDA-compliant environmental monitoring, alarming, reporting and temperature/humidity technology. The 10-step Guide is designed to help the wide range of pharmaceutical processors, blood and tissue banks, clinical laboratories, medical device manufacturers, research hospitals, and other GxP facilities who may receive public criticism warning letters respond quickly and appropriately within the permitted 15-day window. Proper FDA 483 letter response is critical to both help in reputation repair and for real remediation actions to assure a quality process and patient safety.
FDA 483 letters are expected to increase this year, reflecting the FDA’s recent staff expansion and rewrite of the FDA 483 Letter rules to narrow response time to the new 15-day window.
Ken Appel, Veriteq Manager Regulated Markets, comments, "Veriteq is keenly aware of the great number of FDA-regulated companies that thought they were in full compliance but were not when it came to temperature monitoring. Since Veriteq offers the only monitoring system that ensures both gap-free records and accuracy in between calibration intervals we have always had customers who came to Veriteq because they were using inferior solutions. Customers are often disappointed over the failure of chart recorders or data loggers to record data during facility power outages, hold calibration accuracy of sensors or other equipment failure that had triggered negative FDA actions or product loss. If and when a company receives a Warning Letter it is a matter of public record listed on the FDA's web site. Veriteq's guide-"How to Avoid and Respond to Public FDA Criticisms-Form 483 Letters-for Temperature, Humidity and other Controlled Environments" will help quality departments that have received such public criticism regroup, but more importantly, will give some best-practice tips that will help FDA-regulated organizations avoid Warning Letters in the first place."
To obtain a copy of the Guide fill out the request form at http://www.veriteq.com/fda_response.htm or contact: Janice Bennett, Veriteq Marketing Manager, 800-683-8374 (or +1-604-273-6850 outside North America), FAX 604-273-2874.
Veriteq Instruments (www.veriteq.com), a Vaisala company, provides environmental monitoring of temperature, humidity and other critical variables in controlled environments for regulated industries and other critical storage applications where product loss or audit failures are unacceptable. A network of independent data recorders equipped with industry-best 10-year batteries deliver monitoring, alarming and reporting with a continuous record of data, immune from power outages and network interruptions. Headquartered in Richmond, BC, with a worldwide distributor network Veriteq serves thousands of users, from Global 500 companies and major learning, standards and government institutions to mid-sized research and manufacturing organizations.
Vaisala is a global leader in environmental and industrial measurement. Building on more than 70 years of experience, Vaisala contributes to a better quality of life by providing a comprehensive range of innovative observation and measurement products and services for meteorology, weather critical operations and controlled environments. Headquartered in Finland, Vaisala employs over 1400 professionals worldwide and is listed on the NASDAQ OMX Helsinki. www.vaisala.com For more information: Pirjo Kortteisto, Director, Cleanrooms & Chambers, tel. +358 40 7683 826, or Liisa Ahtiluoto, Communications Manager, tel. +358 40 730 7695
Please address editorial inquiries to Amy Munice, ALM Communications, alm(at)almcommunications(dot)com, +1-773-862-6800, (skype) ALMCommunications.
# # #
Read the full story at http://www.prweb.com/releases/Veriteq/FDA_483/prweb3937084.htm.
Copyright©2010 Vocus, Inc.
All rights reserved